These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

801 related items for PubMed ID: 27391453

  • 21. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
    Nosrati A, Monabati A, Sadeghipour A, Radmanesh F, Safaei A, Movahedinia S.
    Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting.
    Thirunavukkarasu B, Bal A, Prakash G, Malhotra P, Singh H, Das A.
    Appl Immunohistochem Mol Morphol; 2022 Jan 01; 30(1):49-55. PubMed ID: 34456240
    [Abstract] [Full Text] [Related]

  • 24. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q, Xu-Monette ZY, Tzankov A, Deng L, Wang X, Manyam GC, Visco C, Montes-Moreno S, Zhang L, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, Medeiros LJ, Hu S, Young KH.
    Oncotarget; 2016 Jan 19; 7(3):2401-16. PubMed ID: 26573234
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma.
    Moore AM, Moshkin O, Swain GJ, Crocker S, LeBrun DP.
    Diagn Pathol; 2018 May 24; 13(1):34. PubMed ID: 29793519
    [Abstract] [Full Text] [Related]

  • 27. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
    Mationg-Kalaw E, Tan LH, Tay K, Lim ST, Tang T, Lee YY, Tan SY.
    Histopathology; 2012 Dec 24; 61(6):1214-8. PubMed ID: 23171357
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. C-MYC and BCL2 translocation frequency in diffuse large B-cell lymphomas: A study of 97 patients.
    Akkaya B, Salim O, Akkaya H, Ozcan M, Yucel OK, Erdem R, Iltar U, Undar L.
    Indian J Pathol Microbiol; 2016 Dec 24; 59(1):41-6. PubMed ID: 26960633
    [Abstract] [Full Text] [Related]

  • 30. Immunophenotypic and cytogenetic findings of B-lymphoblastic leukemia/lymphoma associated with combined IGH/BCL2 and MYC rearrangement.
    Kelemen K, Holden J, Johnson LJ, Davion S, Robetorye RS.
    Cytometry B Clin Cytom; 2017 Jul 24; 92(4):310-314. PubMed ID: 26517296
    [Abstract] [Full Text] [Related]

  • 31. Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases.
    Agarwal R, Lade S, Liew D, Rogers TM, Byrne D, Feleppa F, Juneja S, Westerman DA.
    J Clin Pathol; 2016 Mar 24; 69(3):266-70. PubMed ID: 26307073
    [Abstract] [Full Text] [Related]

  • 32. Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.
    Dunleavy K.
    Curr Treat Options Oncol; 2015 Dec 24; 16(12):58. PubMed ID: 26634708
    [Abstract] [Full Text] [Related]

  • 33. Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab.
    Kobayashi T, Tsutsumi Y, Sakamoto N, Nagoshi H, Yamamoto-Sugitani M, Shimura Y, Mizutani S, Matsumoto Y, Nishida K, Horiike S, Asano N, Nakamura S, Kuroda J, Taniwaki M.
    Jpn J Clin Oncol; 2012 Nov 24; 42(11):1035-42. PubMed ID: 22984125
    [Abstract] [Full Text] [Related]

  • 34. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.
    Hori Y, Yamamoto H, Nozaki Y, Torisu T, Fujiwara M, Taguchi K, Nishiyama K, Nakamura S, Kitazono T, Oda Y.
    Hum Pathol; 2020 Feb 24; 96():67-78. PubMed ID: 31734190
    [Abstract] [Full Text] [Related]

  • 35. Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci.
    Adams T, Fuchs D, Shadoan PK, Johnstone L, Lau BM, McGhan L, Anwer F, Al-Kateb H.
    Cancer Genet; 2018 Apr 24; 222-223():25-31. PubMed ID: 29666005
    [Abstract] [Full Text] [Related]

  • 36. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP, Mihaljevic B, Jakovic L, Martinovic VC, Fekete MD, Andjelic B, Antic D, Bogdanovic A, Boricic N, Terzic T, Jelicic J, Milenkovic S.
    J BUON; 2015 Apr 24; 20(3):820-8. PubMed ID: 26214636
    [Abstract] [Full Text] [Related]

  • 37. Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome.
    Caponetti GC, Dave BJ, Perry AM, Smith LM, Jain S, Meyer PN, Bast M, Bierman PJ, Bociek RG, Vose JM, Armitage JO, Aoun P, Fu K, Greiner TC, Chan WC, Sanger WG, Weisenburger DD.
    Leuk Lymphoma; 2015 Apr 24; 56(11):3082-9. PubMed ID: 25827211
    [Abstract] [Full Text] [Related]

  • 38. Further Exploration of the Complexities of Large B-Cell Lymphomas With MYC Abnormalities and the Importance of a Blastoid Morphology.
    Moore EM, Aggarwal N, Surti U, Swerdlow SH.
    Am J Surg Pathol; 2017 Sep 24; 41(9):1155-1166. PubMed ID: 28614202
    [Abstract] [Full Text] [Related]

  • 39. Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study).
    Hilton LK, Collinge B, Ben-Neriah S, Alduaij W, Shaalan H, Weng AP, Cruz M, Slack GW, Farinha P, Miyata-Takata T, Boyle M, Meissner B, Cook JR, Ondrejka SL, Ott G, Rosenwald A, Campo E, Amador C, Greiner TC, Raess PW, Song JY, Inghirami G, Jaffe ES, Weisenburger DD, Chan WC, Beiske K, Fu K, Delabie J, Pittaluga S, Iqbal J, Wright G, Sehn LH, Savage KJ, Mungall AJ, Feldman AL, Staudt LM, Steidl C, Rimsza LM, Morin RD, Scott DW.
    Blood; 2024 Aug 01; 144(5):525-540. PubMed ID: 38701426
    [Abstract] [Full Text] [Related]

  • 40. BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase.
    Zou D, Yi S, Cui R, Liu W, Li C, Zhong S, Yu Z, Li Z, Lv R, Ru K, Wang H, An G, Xu Y, Qiu L.
    BMC Med Genet; 2017 Feb 16; 18(1):16. PubMed ID: 28209136
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.